Ardelyx Leads The Pack Of 3 Promising Penny Stocks

The market has been flat over the last week but is up 11% over the past year, with earnings forecast to grow by 15% annually. For investors willing to explore beyond established giants, penny stocks—despite their somewhat outdated name—can still offer surprising value. These stocks often represent smaller or newer companies and, when backed by strong financials, can provide a mix of affordability and growth potential.

Top 10 Penny Stocks In The United States

Click here to see the full list of 451 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Ardelyx (ARDX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of approximately $868.50 million.

Operations: The company's revenue is primarily derived from the development and commercialization of biopharmaceutical products, totaling $361.71 million.

Market Cap: $868.5M

Ardelyx, Inc. has been actively working towards reducing its losses, achieving a 15.8% annual reduction over the past five years despite remaining unprofitable. Recent executive changes and strategic presentations underscore its focus on long-term growth and value creation. The company reported US$74.11 million in revenue for Q1 2025, showing an increase from the previous year, although it still faces a net loss of US$41.14 million for the same period. Ardelyx's short-term assets significantly surpass both its short- and long-term liabilities, providing financial stability amidst ongoing challenges in profitability and debt management.

• Click to explore a detailed breakdown of our findings in Ardelyx's financial health report.
• Review our growth performance report to gain insights into Ardelyx's future.

Autolus Therapeutics (AUTL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $588.17 million.

Operations: The company's revenue primarily comes from developing and commercializing CAR-T therapies, totaling $9.01 million.

Market Cap: $588.17M

Autolus Therapeutics, while currently unprofitable, shows potential in the biotech penny stock space with promising developments in CAR-T therapies. The company has a robust cash position of US$615.8 million, exceeding both short- and long-term liabilities, which provides financial stability. Recent presentations at the European Hematology Association Congress highlighted significant progress in its FELIX study for obe-cel, showing durable remissions without new safety concerns. However, volatility remains high and profitability is not expected within the next three years despite projected revenue growth of 49.32% annually from its current US$9.01 million base.

• Get an in-depth perspective on Autolus Therapeutics' performance by reading our balance sheet health report here.
• Learn about Autolus Therapeutics' future growth trajectory here.

Fortitude Gold (FTCO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Fortitude Gold Corporation operates as a mining company exploring for gold and silver projects in the United States, with a market cap of $92.64 million.

Operations: The company's revenue is derived entirely from its Metals & Mining segment, specifically focused on Gold & Other Precious Metals, generating $35.69 million.

Market Cap: $92.64M

Fortitude Gold Corporation, with a market cap of US$92.64 million, is navigating the penny stock landscape with a focus on gold and silver mining. Despite being unprofitable and experiencing declining earnings over the past five years, it reported Q1 2025 sales of US$6.54 million and net income of US$1.25 million, marking an improvement from a previous loss. The company maintains financial stability with short-term assets exceeding liabilities and no debt burden. However, its dividend yield is not well supported by earnings or free cash flow, raising concerns about sustainability amid production challenges noted in recent operating results.

• Click here to discover the nuances of Fortitude Gold with our detailed analytical financial health report.
• Examine Fortitude Gold's past performance report to understand how it has performed in prior years.

Next Steps

• Unlock our comprehensive list of 451 US Penny Stocks by clicking here.
• Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com